ChargeExpo 2024: How Advanced Conductors Can Enhance EV Infrastructure and Revolutionize the Energy Sector

 

The U.S. power grid is struggling, and it’s no wonder why: The aging grid was not built for a time when clean energy sources would begin to replace fossil fuels. With an increasing number of Americans expected to switch to electric vehicles in the coming years, the need to decarbonize the power grid and enhance electric vehicle (EV) infrastructure is urgent. Innovative solutions, like advanced conductors that promise to revolutionize the energy sector, are the need of the hour.

But what challenges do we face in integrating these advanced conductors into our existing infrastructure, and how can we overcome them to ensure a sustainable energy future? Daniel Litwin, the Voice of B2B at MarketScale, sat down with Dr. Jason Huang, the founder of TS Conductor, on the show floor of ChargeExpo 2024 to gain insights into the future of the energy sector. As the official media partner of the event, MarketScale had the privilege of engaging in a thought-provoking conversation with Dr. Huang.

The duo delved into several key topics:

  • The critical role of advanced conductors in the energy transition, enabling the integration of renewable energy sources into the grid.
  • The challenges of modernizing the aging power grid infrastructure to accommodate the increasing demand for electricity and the shift towards EVs.
  • Strategies for overcoming institutional and regulatory barriers to the adoption of advanced conductor technology for grid decarbonization.

Dr. Jason Huang, with his extensive background in engineering and commitment to sustainable energy solutions, brings a wealth of knowledge to the table. As the founder of TS Conductor, he is at the forefront of developing advanced conductors that are poised to play a pivotal role in the energy transition.

Article written by MarketScale.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More